English

Cordyceps Sunshine Biotech Holdings Co., Ltd.

EDGAR

Report (type unavailable) · filed 2026-09-02

Annual consolidated revenue for 2025: about USD 1.245M, using the latest reported figures. The previous period, 2024, was about USD 1.253M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Short annual reporting periods

These figures cover less than a full year. They are not annualized and are excluded from full-year trends and comparisons.

Reported figures

Measure	Period	Value
Capital expenditure	2020-05-04 – 2020-12-31	1111749 USD Source Dispute
Cost of revenue	2020-05-04 – 2020-12-31	40648 USD Source Dispute
Gross profit	2020-05-04 – 2020-12-31	94072 USD Source Dispute
Net income	2020-05-04 – 2020-12-31	-13476 USD Source Dispute
Operating cash flow	2020-05-04 – 2020-12-31	-130549 USD Source Dispute
Operating expenses	2020-05-04 – 2020-12-31	85340 USD Source Dispute
Operating income	2020-05-04 – 2020-12-31	8732 USD Source Dispute
Revenue	2020-05-04 – 2020-12-31	134720 USD Source Dispute

Latest quarter

Revenue

316 thousand

2023 Q4 ·

Exact inputs and evidence

Revenue: 882533 USD Source
Revenue: 567031 USD Source

Operating margin

38.18%

2023 Q4 · %

Exact inputs and evidence

Operating Income: 227833 USD Source
Operating Income: 107385 USD Source
Revenue: 882533 USD Source
Revenue: 567031 USD Source

Operating cash flow

-1.23 million

2023 Q4 ·

Exact inputs and evidence

Operating Cash Flow: 359724 USD Source
Operating Cash Flow: 1592448 USD Source

Cash and cash equivalents: 3.2 thousand USD 2025-12-31 Source
Exact value

3199 USD
Long-term debt including current maturities: Not available
Shares outstanding: 111 million shares 2025-12-31 Source
Exact value

111120000 shares

Reported share-count change

0.00% · 0 shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

111120000 shares · 2024-12-31· Source
111120000 shares · 2025-12-31· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-09-02.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2025-12-31
Operating income: 5 of 11 periods available· newest 2025-12-31
Net income: 5 of 11 periods available· newest 2025-12-31
Operating cash flow: 5 of 11 periods available· newest 2025-12-31
Capital expenditure: 4 of 11 periods available· newest 2024-12-31
Total assets: 5 of 11 periods available· newest 2025-12-31
Total liabilities: 5 of 11 periods available· newest 2025-12-31
Current assets: 5 of 11 periods available· newest 2025-12-31
Current liabilities: 5 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 5 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-0.6%

Prior period

USD 1.25 million

2024-01-01 – 2024-12-31
Current period

USD 1.25 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1245348 − 1253484 = -8136 USD

1253484 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1245348 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2025-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Year-over-year change in Revenue: -8136 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1245348 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#622314 Filing: 000121390026057774 Input fundies:Revenue: 1253484 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#622733 Filing: 000121390026057774
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 71,436

Prior period

−USD 226,258

2024-01-01 – 2024-12-31
Current period

−USD 154,822

2025-01-01 – 2025-12-31

Exact inputs and evidence

-154822 − -226258 = 71436 USD

-226258 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-154822 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2025-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Year-over-year change in Net income: 71436 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -154822 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#838052 Filing: 000121390026057774 Input fundies:NetIncome: -226258 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#678768 Filing: 000121390026057774
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-111.5%

Prior period

USD 312,006

2024-01-01 – 2024-12-31
Current period

−USD 35,845

2025-01-01 – 2025-12-31

Exact inputs and evidence

-35845 − 312006 = -347851 USD

312006 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-35845 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2025-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Year-over-year change in Operating cash flow: -347851 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -35845 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#719224 Filing: 000121390026057774 Input fundies:OperatingCashFlow: 312006 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#719678 Filing: 000121390026057774
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 1.25 million 100% of revenue
Cost of revenue USD 484,607 39% of revenue
Operating expenses USD 901,869 72% of revenue
Operating income −USD 141,128 −11% of revenue
Tax, interest and other Derived USD 13,694 1.1% of revenue
Net income −USD 154,822 −12% of revenue

Cash

Operating cash flow −USD 35,845 −2.9% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2021 Operating loss: operating costs were 114% of revenue.
2022 Operating loss: operating costs were 879% of revenue.
2023 Net income was higher than operating income, so the split is not drawn.
2024 Operating loss: operating costs were 115% of revenue.
2025 Operating loss: operating costs were 111% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2021 2021-01-01 – 2021-12-31	879318	998705 Derived	-119387	371619 Derived	-491006	-465363 Derived	Source 2021-01-01 – 2021-12-31: 879318 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -119387 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -491006 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -365363 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 100000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	53304	468425 Derived	-415121	304972 Derived	-720093	-321853 Derived	Source 2022-01-01 – 2022-12-31: 53304 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -415121 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -720093 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -321378 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 475 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	882533	654700 Derived	227833	-523776 Derived	751609	40237 Derived	Source 2023-01-01 – 2023-12-31: 882533 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: 227833 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 751609 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: 359724 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 319487 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	1253484	1437397 Derived	-183913	42345 Derived	-226258	-37231 Derived	Source 2024-01-01 – 2024-12-31: 1253484 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -183913 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -226258 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 312006 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 349237 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	1245348	1386476 Derived	-141128	13694 Derived	-154822	Unavailable	Source 2025-01-01 – 2025-12-31: 1245348 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -141128 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -154822 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -35845 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1.2M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Revenue	879318	Revenue: 879318 Open source
20222022-12-31	Revenue	53304	Revenue: 53304 Open source
20232023-12-31	Revenue	882533	Revenue: 882533 Open source
20242024-12-31	Revenue	1253484	Revenue: 1253484 Open source
20252025-12-31	Revenue	1245348	Revenue: 1245348 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-0.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Year over year	No prior comparable period	Revenue: 879318 Open source
20222022-12-31	Year over year	-93.9%	Revenue: 53304 Open source Revenue: 879318 Open source
20232023-12-31	Year over year	1,555.7%	Revenue: 882533 Open source Revenue: 53304 Open source
20242024-12-31	Year over year	42%	Revenue: 1253484 Open source Revenue: 882533 Open source
20252025-12-31	Year over year	-0.6%	Revenue: 1245348 Open source Revenue: 1253484 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -11.3% 2025

Net margin -12.4% 2025

Free cash flow margin -3% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Operating margin	-13.6%	Operating Income: -119387 Open source Revenue: 879318 Open source
20222022-12-31	Operating margin	-778.8%	Operating Income: -415121 Open source Revenue: 53304 Open source
20232023-12-31	Operating margin	25.8%	Operating Income: 227833 Open source Revenue: 882533 Open source
20242024-12-31	Operating margin	-14.7%	Operating Income: -183913 Open source Revenue: 1253484 Open source
20252025-12-31	Operating margin	-11.3%	Operating Income: -141128 Open source Revenue: 1245348 Open source
20212021-12-31	Net margin	-55.8%	Net Income: -491006 Open source Revenue: 879318 Open source
20222022-12-31	Net margin	-1,350.9%	Net Income: -720093 Open source Revenue: 53304 Open source
20232023-12-31	Net margin	85.2%	Net Income: 751609 Open source Revenue: 882533 Open source
20242024-12-31	Net margin	-18.1%	Net Income: -226258 Open source Revenue: 1253484 Open source
20252025-12-31	Net margin	-12.4%	Net Income: -154822 Open source Revenue: 1245348 Open source
20212021-12-31	Free cash flow margin	-52.9%	Revenue: 879318 Open source Operating Cash Flow: -365363 Open source Capital Expenditure: 100000 Open source
20222022-12-31	Free cash flow margin	-603.8%	Revenue: 53304 Open source Operating Cash Flow: -321378 Open source Capital Expenditure: 475 Open source
20232023-12-31	Free cash flow margin	4.6%	Revenue: 882533 Open source Operating Cash Flow: 359724 Open source Capital Expenditure: 319487 Open source
20242024-12-31	Free cash flow margin	-3%	Revenue: 1253484 Open source Operating Cash Flow: 312006 Open source Capital Expenditure: 349237 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 1245348 Open source Operating Cash Flow: -35845 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -35.8K 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Operating cash flow	-365363	Operating Cash Flow: -365363 Open source
20222022-12-31	Operating cash flow	-321378	Operating Cash Flow: -321378 Open source
20232023-12-31	Operating cash flow	359724	Operating Cash Flow: 359724 Open source
20242024-12-31	Operating cash flow	312006	Operating Cash Flow: 312006 Open source
20252025-12-31	Operating cash flow	-35845	Operating Cash Flow: -35845 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -37.2K 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20212021-12-31	Free cash flow	-465363	Operating Cash Flow: -365363 Open source Capital Expenditure: 100000 Open source
20222022-12-31	Free cash flow	-321853	Operating Cash Flow: -321378 Open source Capital Expenditure: 475 Open source
20232023-12-31	Free cash flow	40237	Operating Cash Flow: 359724 Open source Capital Expenditure: 319487 Open source
20242024-12-31	Free cash flow	-37231	Operating Cash Flow: 312006 Open source Capital Expenditure: 349237 Open source
20252025-12-31	Free cash flow	Unavailable	Operating Cash Flow: -35845 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

111.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Liabilities / assets	108.5%	Total Liabilities: 3538851 Open source Total Assets: 3263038 Open source
20222022-12-31	Liabilities / assets	145.2%	Total Liabilities: 3056187 Open source Total Assets: 2104853 Open source
20232023-12-31	Liabilities / assets	104.5%	Total Liabilities: 3503578 Open source Total Assets: 3351782 Open source
20242024-12-31	Liabilities / assets	108.1%	Total Liabilities: 4999247 Open source Total Assets: 4623704 Open source
20252025-12-31	Liabilities / assets	111.5%	Total Liabilities: 5192062 Open source Total Assets: 4657511 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.19× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20212021-12-31	Current assets / current liabilities	0.39×	Current Assets: 1130828 Open source Current Liabilities: 2921526 Open source
20222022-12-31	Current assets / current liabilities	0.2×	Current Assets: 501552 Open source Current Liabilities: 2521130 Open source
20232023-12-31	Current assets / current liabilities	0.11×	Current Assets: 327175 Open source Current Liabilities: 2966143 Open source
20242024-12-31	Current assets / current liabilities	0.12×	Current Assets: 601602 Open source Current Liabilities: 4986645 Open source
20252025-12-31	Current assets / current liabilities	0.19×	Current Assets: 997742 Open source Current Liabilities: 5192062 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2021 2021-01-01 – 2021-12-31	−USD 491,006 Exact value Exact value: -491006 USD 2021-01-01 – 2021-12-31: -491006 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2021-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Net Income: -491006 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -491006 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390025090714/ea0254870-20fa2_cordyceps.htm#952392 Filing: 000121390025090714 The citation records this snapshot. The page link may show a newer release later.	−USD 365,363 Exact value Exact value: -365363 USD 2021-01-01 – 2021-12-31: -365363 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2021-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Operating Cash Flow: -365363 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -365363 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390025090714/ea0254870-20fa2_cordyceps.htm#1018079 Filing: 000121390025090714 The citation records this snapshot. The page link may show a newer release later.	USD 100,000 Exact value Exact value: 100000 USD 2021-01-01 – 2021-12-31: 100000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2021-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Capital Expenditure: 100000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390025090714/ea0254870-20fa2_cordyceps.htm#1022184 Filing: 000121390025090714 The citation records this snapshot. The page link may show a newer release later.	−USD 465,363 Calculation and evidence -365363 − 100000 USD Exact free cash flow: -465363 USD 2021-01-01 – 2021-12-31: -365363 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 100000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2021-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Free cash flow: -465363 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -365363 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390025090714/ea0254870-20fa2_cordyceps.htm#1018079 Filing: 000121390025090714 Input fundies:CapitalExpenditure: 100000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390025090714/ea0254870-20fa2_cordyceps.htm#1022184 Filing: 000121390025090714 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 720,093 Exact value Exact value: -720093 USD 2022-01-01 – 2022-12-31: -720093 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2022-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Net Income: -720093 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -720093 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390025090714/ea0254870-20fa2_cordyceps.htm#966218 Filing: 000121390025090714 The citation records this snapshot. The page link may show a newer release later.	−USD 321,378 Exact value Exact value: -321378 USD 2022-01-01 – 2022-12-31: -321378 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2022-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Operating Cash Flow: -321378 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -321378 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390025090714/ea0254870-20fa2_cordyceps.htm#1017490 Filing: 000121390025090714 The citation records this snapshot. The page link may show a newer release later.	USD 475 Exact value Exact value: 475 USD 2022-01-01 – 2022-12-31: 475 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2022-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Capital Expenditure: 475 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 475 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390023039368/f20f2022_cordycep.htm#1007875 Filing: 000121390023039368 The citation records this snapshot. The page link may show a newer release later.	−USD 321,853 Calculation and evidence -321378 − 475 USD Exact free cash flow: -321853 USD 2022-01-01 – 2022-12-31: -321378 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 475 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2022-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Free cash flow: -321853 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -321378 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390025090714/ea0254870-20fa2_cordyceps.htm#1017490 Filing: 000121390025090714 Input fundies:CapitalExpenditure: 475 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390023039368/f20f2022_cordycep.htm#1007875 Filing: 000121390023039368 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	USD 751,609 Exact value Exact value: 751609 USD 2023-01-01 – 2023-12-31: 751609 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2023-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Net Income: 751609 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: 751609 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#673039 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.	USD 359,724 Exact value Exact value: 359724 USD 2023-01-01 – 2023-12-31: 359724 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2023-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Operating Cash Flow: 359724 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 359724 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#720130 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.	USD 319,487 Exact value Exact value: 319487 USD 2023-01-01 – 2023-12-31: 319487 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2023-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Capital Expenditure: 319487 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 319487 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#722291 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.	USD 40,237 Calculation and evidence 359724 − 319487 USD Exact free cash flow: 40237 USD 2023-01-01 – 2023-12-31: 359724 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 319487 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2023-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Free cash flow: 40237 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 359724 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#720130 Filing: 000121390026057774 Input fundies:CapitalExpenditure: 319487 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#722291 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 226,258 Exact value Exact value: -226258 USD 2024-01-01 – 2024-12-31: -226258 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2024-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Net Income: -226258 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -226258 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#678768 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.	USD 312,006 Exact value Exact value: 312006 USD 2024-01-01 – 2024-12-31: 312006 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2024-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Operating Cash Flow: 312006 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 312006 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#719678 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.	USD 349,237 Exact value Exact value: 349237 USD 2024-01-01 – 2024-12-31: 349237 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2024-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Capital Expenditure: 349237 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 349237 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#721964 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.	−USD 37,231 Calculation and evidence 312006 − 349237 USD Exact free cash flow: -37231 USD 2024-01-01 – 2024-12-31: 312006 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 349237 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2024-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Free cash flow: -37231 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 312006 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#719678 Filing: 000121390026057774 Input fundies:CapitalExpenditure: 349237 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#721964 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 154,822 Exact value Exact value: -154822 USD 2025-01-01 – 2025-12-31: -154822 USD Inspect Net Income Open source Share or cite Citation for Net Income · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2025-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Net Income: -154822 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -154822 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#838052 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.	−USD 35,845 Exact value Exact value: -35845 USD 2025-01-01 – 2025-12-31: -35845 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Cordyceps Sunshine Biotech Holdings Co., Ltd. · 2025-12-31 Cordyceps Sunshine Biotech Holdings Co., Ltd. (edgar:1885680) Operating Cash Flow: -35845 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-06T13:21:10Z Snapshot: c1c1c7a2e9c234c9f8eeddae5dc416c4f05ba55f551639e1bb89a8556b1eaaa8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1885680/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35845 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1885680/000121390026057774/ea0290487-20f_cordyceps.htm#719224 Filing: 000121390026057774 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

15 filings · 406 latest values · 406 originally reported values

Dataset published 2026-11-06. Source filing dates and reporting periods are shown separately.

Identifiers: 0001885680, 1885680, None, edgar:1885680

Also known as Cordyceps Sunshine Biotech Holdings Co., Ltd., TFA Therapeutics, Inc.

Cordyceps Sunshine Biotech Holdings Co., Ltd.

Short annual reporting periods

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation